Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2016, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 73, 71, 4, 65, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 6, 9 and 1 molecules, respectively.
Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG
AbbVie Inc
Acceleron Pharma Inc
Adaptimmune Therapeutics Plc
Aduro BioTech Inc
Advanced Cancer Therapeutics
Advenchen Laboratories LLC
Affitech A/S
Alethia Biotherapeutics Inc
Altor BioScience Corp
Ambrx Inc
Amgen Inc
Ampio Pharmaceuticals Inc
Apac Biotech Pvt Ltd
Apcure SAS
APEIRON Biologics AG
Aphios Corp
Aptevo Therapeutics Inc
Aravive Biologics Inc
arGEN-X BV
Argos Therapeutics Inc
ARMO Biosciences Inc
ArQule Inc
Arrowhead Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
ATLAB Pharma SAS
Bayer AG
BeiGene Ltd
Berg LLC
Bio-Cancer Treatment International Ltd
Biocad
Bionomics Ltd
Bionovis SA
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
CASI Pharmaceuticals Inc
Celgene Corp
Cellceutix Corp
Celldex Therapeutics Inc
Cellular Biomedicine Group Inc
Chipscreen Biosciences Ltd
Cleave Biosciences Inc
COARE Biotechnology Inc
Coherus BioSciences Inc
Corcept Therapeutics Inc
Corvus Pharmaceuticals Inc
Cytune Pharma SAS
Daiichi Sankyo Company Ltd
Dr. Reddy's Laboratories Ltd
Ecrins Therapeutics SAS
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Company
Esperance Pharmaceuticals Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Gene Techno Science Co Ltd
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Glycotope GmbH
HEC Pharm Co Ltd
Hemispherx Biopharma Inc
Horizon Pharma Plc
Hutchison MediPharma Ltd
Immatics Biotechnologies GmbH
Immune Design Corp
Immunicum AB
ImmunoFrontier Inc
ImmunoGen Inc
Immunomedics Inc
Incuron LLC
Incyte Corp
Innate Immunotherapeutics Ltd
Inspyr Therapeutics Inc
Intech Biopharm Ltd
Johnson & Johnson
KAHR medical Ltd
Karyopharm Therapeutics Inc
KineMed Inc
Komipharm International Co Ltd
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
Mabion SA
MacroGenics Inc
MaxiVAX SA
MediaPharma srl
MedImmune LLC
Medivation Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Molecular Partners AG
Moleculin Biotech Inc
Monopar Therapeutics LLC
Mycenax Biotech Inc
NanoSmart Pharmaceuticals Inc
Nektar Therapeutics
NewLink Genetics Corp
Novartis AG
NovaTarg Therapeutics Inc
Omeros Corp
OncBioMune Pharmaceuticals Inc
Oncobiologics Inc
Oncolys BioPharma Inc
OncoMax
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Peloton Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pharmacyclics Inc
Pharmicell Co Ltd
Pivotal BioSciences Inc
Prima BioMed Ltd
PsiOxus Therapeutics Ltd
Recombio SL
Rexahn Pharmaceuticals Inc
Richter Gedeon Nyrt
Sanofi
Selvita SA
Sevion Therapeutics Inc
Shanghai Henlius Biotech Co Ltd
Sillajen Biotherapeutics
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Taiwan Liposome Company Ltd
Takeda Pharmaceutical Company Ltd
Tara Immuno-Oncology Therapeutics LLC
Taris Biomedical LLC
TC BioPharm Ltd
Teva Pharmaceutical Industries Ltd
Theravectys SA
Tocagen Inc
TRACON Pharmaceuticals Inc
TVAX Biomedical Inc
Tyrogenex Inc
UroGen Pharmaceuticals Ltd
Valeant Pharmaceuticals International Inc
Vascular Biogenics Ltd
Vault Pharma Inc
Vaxeal Holding SA
Vyriad Inc
X4 Pharmaceuticals Inc
'
Table of Contents
Table of Contents 2
Introduction 8
Kidney Cancer (Renal Cell Cancer) Overview 9
Therapeutics Development 10
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Development by Companies 12
Kidney Cancer (Renal Cell Cancer) - Therapeutics under Investigation by Universities/Institutes 23
Kidney Cancer (Renal Cell Cancer) - Pipeline Products Glance 25
Kidney Cancer (Renal Cell Cancer) - Products under Development by Companies 29
Kidney Cancer (Renal Cell Cancer) - Products under Investigation by Universities/Institutes 49
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 51
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 201
Drug Profiles 235
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1040
Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1064
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1069
Appendix 1083
List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016 39
Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Development by Companies, H2 2016 (Contd..1) 42
Number of Products under Development by Companies, H2 2016 (Contd..2) 43
Number of Products under Development by Companies, H2 2016 (Contd..3) 44
Number of Products under Development by Companies, H2 2016 (Contd..4) 45
Number of Products under Development by Companies, H2 2016 (Contd..5) 46
Number of Products under Development by Companies, H2 2016 (Contd..6) 47
Number of Products under Development by Companies, H2 2016 (Contd..7) 48
Number of Products under Development by Companies, H2 2016 (Contd..8) 49
Number of Products under Development by Companies, H2 2016 (Contd..9) 50
Number of Products under Development by Companies, H2 2016 (Contd..10) 51
Number of Products under Investigation by Universities/Institutes, H2 2016 53
Comparative Analysis by Late Stage Development, H2 2016 54
Comparative Analysis by Clinical Stage Development, H2 2016 55
Comparative Analysis by Early Stage Development, H2 2016 56
Comparative Analysis by Unknown Stage Development, H2 2016 57
Products under Development by Companies, H2 2016 58
Products under Development by Companies, H2 2016 (Contd..1) 59
Products under Development by Companies, H2 2016 (Contd..2) 60
Products under Development by Companies, H2 2016 (Contd..3) 61
Products under Development by Companies, H2 2016 (Contd..4) 62
Products under Development by Companies, H2 2016 (Contd..5) 63
Products under Development by Companies, H2 2016 (Contd..6) 64
Products under Development by Companies, H2 2016 (Contd..7) 65
Products under Development by Companies, H2 2016 (Contd..8) 66
Products under Development by Companies, H2 2016 (Contd..9) 67
Products under Development by Companies, H2 2016 (Contd..10) 68
Products under Development by Companies, H2 2016 (Contd..11) 69
Products under Development by Companies, H2 2016 (Contd..12) 70
Products under Development by Companies, H2 2016 (Contd..13) 71
Products under Development by Companies, H2 2016 (Contd..14) 72
Products under Development by Companies, H2 2016 (Contd..15) 73
Products under Development by Companies, H2 2016 (Contd..16) 74
Products under Development by Companies, H2 2016 (Contd..17) 75
Products under Development by Companies, H2 2016 (Contd..18) 76
Products under Development by Companies, H2 2016 (Contd..19) 77
Products under Investigation by Universities/Institutes, H2 2016 78
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 79
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H2 2016 80
Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H2 2016 81
Kidney Cancer (Renal Cell Cancer) - Pipeline by Acceleron Pharma Inc, H2 2016 82
Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 83
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aduro BioTech Inc, H2 2016 84
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics, H2 2016 85
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H2 2016 86
Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H2 2016 87
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc, H2 2016 88
Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corp, H2 2016 89
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx Inc, H2 2016 90
Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc, H2 2016 91
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 92
Kidney Cancer (Renal Cell Cancer) - Pipeline by Apac Biotech Pvt Ltd, H2 2016 93
Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H2 2016 94
Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H2 2016 95
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aphios Corp, H2 2016 96
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aptevo Therapeutics Inc, H2 2016 97
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aravive Biologics Inc, H2 2016 98
Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H2 2016 99
Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics Inc, H2 2016 100
Kidney Cancer (Renal Cell Cancer) - Pipeline by ARMO Biosciences Inc, H2 2016 101
Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule Inc, H2 2016 102
Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016 103
Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc, H2 2016 104
Kidney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H2 2016 105
Kidney Cancer (Renal Cell Cancer) - Pipeline by ATLAB Pharma SAS, H2 2016 106
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H2 2016 107
Kidney Cancer (Renal Cell Cancer) - Pipeline by BeiGene Ltd, H2 2016 108
Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H2 2016 109
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 110
Kidney Cancer (Renal Cell Cancer) - Pipeline by Biocad, H2 2016 111
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Ltd, H2 2016 112
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H2 2016 113
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 114
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical Inc, H2 2016 115
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H2 2016 116
Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences Inc, H2 2016 117
Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc, H2 2016 118
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corp, H2 2016 119
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellceutix Corp, H2 2016 120
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics Inc, H2 2016 121
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 122
Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H2 2016 123
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cleave Biosciences Inc, H2 2016 124
Kidney Cancer (Renal Cell Cancer) - Pipeline by COARE Biotechnology Inc, H2 2016 125
Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences Inc, H2 2016 126
Kidney Cancer (Renal Cell Cancer) - Pipeline by Corcept Therapeutics Inc, H2 2016 127
Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 128
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cytune Pharma SAS, H2 2016 129
Kidney Cancer (Renal Cell Cancer) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 130
Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 131
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H2 2016 132
Kidney Cancer (Renal Cell Cancer) - Pipeline by EirGenix Inc, H2 2016 133
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co Ltd, H2 2016 134
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2016 135
Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 136
Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis Inc, H2 2016 137
Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 138
Kidney Cancer (Renal Cell Cancer) - Pipeline by Five Prime Therapeutics Inc, H2 2016 139
Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co Ltd, H2 2016 140
Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co Ltd, H2 2016 141
Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H2 2016 142
Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H2 2016 143
Kidney Cancer (Renal Cell Cancer) - Pipeline by HEC Pharm Co Ltd, H2 2016 144
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hemispherx Biopharma Inc, H2 2016 145
Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H2 2016 146
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison MediPharma Ltd, H2 2016 147
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 148
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp, H2 2016 149
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H2 2016 150
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier Inc, H2 2016 151
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen Inc, H2 2016 152
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics Inc, H2 2016 153
Kidney Cancer (Renal Cell Cancer) - Pipeline by Incuron LLC, H2 2016 154
Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corp, H2 2016 155
Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 156
Kidney Cancer (Renal Cell Cancer) - Pipeline by Inspyr Therapeutics Inc, H2 2016 157
Kidney Cancer (Renal Cell Cancer) - Pipeline by Intech Biopharm Ltd, H2 2016 158
Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H2 2016 159
Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd, H2 2016 160
Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 161
Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed Inc, H2 2016 162
Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co Ltd, H2 2016 163
Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 164
Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H2 2016 165
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H2 2016 166
Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics Inc, H2 2016 167
Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H2 2016 168
Kidney Cancer (Renal Cell Cancer) - Pipeline by MediaPharma srl, H2 2016 169
Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune LLC, H2 2016 170
Kidney Cancer (Renal Cell Cancer) - Pipeline by Medivation Inc, H2 2016 171
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co Inc, H2 2016 172
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H2 2016 173
Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 174
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc, H2 2016 175
Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H2 2016 176
Kidney Cancer (Renal Cell Cancer) - Pipeline by Moleculin Biotech Inc, H2 2016 177
Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H2 2016 178
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc, H2 2016 179
Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 180
Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H2 2016 181
Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corp, H2 2016 182
Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H2 2016 183
Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics Inc, H2 2016 184
Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corp, H2 2016 185
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc, H2 2016 186
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics Inc, H2 2016 187
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc, H2 2016 188
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H2 2016 189
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoTherapy Science Inc, H2 2016 190
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 191
Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics Inc, H2 2016 192
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc, H2 2016 193
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharma Mar SA, H2 2016 194
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmacyclics Inc, H2 2016 195
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co Ltd, H2 2016 196
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences Inc, H2 2016 197
Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd, H2 2016 198
Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Ltd, H2 2016 199
Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio SL, H2 2016 200
Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 201
Kidney Cancer (Renal Cell Cancer) - Pipeline by Richter Gedeon Nyrt, H2 2016 202
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H2 2016 203
Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita SA, H2 2016 204
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics Inc, H2 2016 205
Kidney Cancer (Renal Cell Cancer) - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016 206
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H2 2016 207
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics Inc, H2 2016 208
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 209
Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 210
Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H2 2016 211
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company Ltd, H2 2016 212
Kidney Cancer (Renal Cell Cancer) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 213
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 214
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H2 2016 215
Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Ltd, H2 2016 216
Kidney Cancer (Renal Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 217
Kidney Cancer (Renal Cell Cancer) - Pipeline by Theravectys SA, H2 2016 218
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc, H2 2016 219
Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 220
Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical Inc, H2 2016 221
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex Inc, H2 2016 222
Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals Ltd, H2 2016 223
Kidney Cancer (Renal Cell Cancer) - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 224
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd, H2 2016 225
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc, H2 2016 226
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H2 2016 227
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vyriad Inc, H2 2016 228
Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals Inc, H2 2016 229
Assessment by Monotherapy Products, H2 2016 230
Assessment by Combination Products, H2 2016 231
Number of Products by Stage and Target, H2 2016 233
Number of Products by Stage and Mechanism of Action, H2 2016 247
Number of Products by Stage and Route of Administration, H2 2016 262
Number of Products by Stage and Molecule Type, H2 2016 264
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H2 2016 1070
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..1), H2 2016 1071
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..2), H2 2016 1072
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..3), H2 2016 1073
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..4), H2 2016 1074
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..5), H2 2016 1075
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..6), H2 2016 1076
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..7), H2 2016 1077
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..8), H2 2016 1078
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..9), H2 2016 1079
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..10), H2 2016 1080
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..11), H2 2016 1081
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..12), H2 2016 1082
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..13), H2 2016 1083
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..14), H2 2016 1084
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..15), H2 2016 1085
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..16), H2 2016 1086
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..17), H2 2016 1087
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..18), H2 2016 1088
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..19), H2 2016 1089
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..20), H2 2016 1090
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..21), H2 2016 1091
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..22), H2 2016 1092
Kidney Cancer (Renal Cell Cancer) - Dormant Projects (Contd..23), H2 2016 1093
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H2 2016 1094
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..1), H2 2016 1095
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..2), H2 2016 1096
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..3), H2 2016 1097
Kidney Cancer (Renal Cell Cancer) - Discontinued Products (Contd..4), H2 2016 1098
List of Figures
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2016 39
Number of Products under Development for Kidney Cancer (Renal Cell Cancer) - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Investigation by Universities/Institutes, H2 2016 52
Comparative Analysis by Late Stage Development, H2 2016 54
Comparative Analysis by Clinical Stage Development, H2 2016 55
Comparative Analysis by Early Stage Products, H2 2016 56
Assessment by Monotherapy Products, H2 2016 230
Assessment by Combination Products, H2 2016 231
Number of Products by Top 10 Targets, H2 2016 232
Number of Products by Stage and Top 10 Targets, H2 2016 232
Number of Products by Top 10 Mechanism of Actions, H2 2016 246
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 246
Number of Products by Top 10 Routes of Administration, H2 2016 261
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 261
Number of Products by Top 10 Molecule Types, H2 2016 263
Number of Products by Stage and Top 10 Molecule Types, H2 2016 263
